➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Baxter
Johnson and Johnson
Dow
Harvard Business School
Boehringer Ingelheim

Last Updated: October 16, 2021

DrugPatentWatch Database Preview

Patent: 10,004,745

➤ Get the DrugPatentWatch Daily Briefing

« Back to Dashboard

Summary for Patent: 10,004,745
Title:Use of inhibitors of Bruton\'S tyrosine kinase (Btk)
Abstract: Disclosed herein are methods for treating a cancer comprising: a. administering a Btk inhibitor to a subject sufficient to result in an increase or appearance in the blood of a subpopulation of lymphocytes defined by immunophenotyping; b. determining the expression profile of one or more biomarkers from one or more subpopulation of lymphocytes; and c. administering a second agent based on the determined expression profile.
Inventor(s): Buggy; Joseph J. (Mountain View, CA), Elias; Laurence (Berkeley, CA), Fyfe; Gwen (San Francisco, CA), Hedrick; Eric (Summit, NJ), Loury; David J. (San Jose, CA), Mody; Tarak D. (Sunnyvale, CA)
Assignee: Pharmacyclics LLC (Sunnyvale, CA)
Application Number:15/066,600
Patent Claims:see list of patent claims

Details for Patent 10,004,745

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Genentech Inc RITUXAN HYCELA rituximab; hyaluronidase (human recombinant) SOLUTION;SUBCUTANEOUS 761064 2017-06-22 ⤷  Free Forever Trial Pharmacyclics LLC (Sunnyvale, CA) 2030-06-03 RX Orphan search
Genentech RITUXAN rituximab SOLUTION;INTRAVENOUS 103705 1997-11-26 ⤷  Free Forever Trial Pharmacyclics LLC (Sunnyvale, CA) 2030-06-03 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

International Patent Family for US Patent 10,004,745

Country Patent Number Estimated Expiration
South Africa 201209381 ⤷  Free Forever Trial
World Intellectual Property Organization (WIPO) 2011153514 ⤷  Free Forever Trial
United States of America 10004746 ⤷  Free Forever Trial
United States of America 10016435 ⤷  Free Forever Trial
United States of America 10478439 ⤷  Free Forever Trial
United States of America 10653696 ⤷  Free Forever Trial
United States of America 10751342 ⤷  Free Forever Trial
>Country >Patent Number >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
AstraZeneca
Dow
Merck
Mallinckrodt
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.